IP Library Granted Patent US 8,716,479
Granted Patent B2
US 8,716,479 · App. 12/810,600 · Granted May 6, 2014

Methods for stereoselective reduction

Inventors: Brian C. Austad (Tewksbury, MA); Andre Lescarbeau (Somerville, MA); Lin-Chen Yu (Quincy, MA)
Assignee: Infinity Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,716,479
App. No.
12/810,600
Granted
May 6, 2014
Kind
B2
Abstract

The invention is directed to a method to reduce a C—C double bond of an enone of a steroidal compound to produce a mixture of β ketone product and α ketone product, comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the presence of a catalyst and a substituted pyridine.

Claims (34)

1. A method of making a mixture of a compound having formula V and a compound having formula VI:

the method comprising treating a compound having formula VII:

in a solvent with hydrogen gas in the presence of a palladium on carbon catalyst and a substituted pyridine, wherein the ratio of the β ketone product V to the α ketone product VI is at least 3:1.

2. The method of claim 1 , wherein the ratio of the compound of formula V to compound of formula VI is at least 10:1, or the ratio of the compound of formula V to compound of formula VI is at least 20:1, or the ratio of the compound of formula V to compound of formula VI is at least 30:1, or the ratio of the compound of formula V to compound of formula VI is at least 40:1.

3. The method of claim 1 , wherein the substituted pyridine is a 3-substituted pyridine.

4. The method of claim 3 , wherein the 3-substituted pyridine is 3-picoline.

5. The method of claim 1 , wherein the substituted pyridine is a 4-substituted pyridine.

6. The method of claim 5 , wherein the 4-substituted pyridine is selected from 4-picoline and 4-methoxypyridine.

7. The method of claim 1 , wherein the solvent comprises the substituted pyridine.

8. The method of claim 7 , wherein the solvent comprises 3-picoline.

9. The method of claim 1 , further comprising adding an aqueous solution of citric acid and isolating the salt of compounds V and VI.

10. The method of claim 9 further comprising making a compound of formula XV:

the method further comprising the steps of:

(a) treating a compound of formula IX:

wherein X − is citrate, CBzCl to produce a compound of formula XI:

wherein PG is CBz;

(b) treating the compound of formula XI with a K-Selectride to produce an alcohol of formula XII:

(c) converting the alcohol of formula XII to an amine of formula XIII:

(d) treating the amine of formula XIII with mewl chloride to produce a sulfonamide of formula XIV:

and

(e) deprotecting the sulfonamide of formula XIV to produce the compound of formula XV.

11. The method of claim 10 , wherein step (c) comprises:

(1) converting the alcohol to a mesylate leaving group to produce a compound of formula XVI:

wherein LG is mesylate;

(2) treating the compound of formula XVI with sodium azide to produce a compound of formula XVII:

and

(3) treating the compound of formula XVII with triphenylphosphine to form the amine of formula XIII.

12. The method of claim 10 , wherein the sulfonamide of formula XIV is deprotected by treatment with hydrogen gas in the presence of a catalyst to form the compound of formula XV.

13. The method of claim 10 , wherein the compound of formula XV has the following absolute stereochemistry:

14. The method of claim 10 , further comprising the step of treating the compound of formula XV with HCl to produce a compound of formula XIX:

wherein X − is chloride.

15. A mixture comprising a compound of formula V, or a pharmaceutically acceptable salt thereof:

and a compound of formula 2c, or a pharmaceutically acceptable salt thereof:

16. The mixture of claim 15 , wherein the compound of formula 2c is present in less than 1%.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2020
From: INFINITY PHARMACEUTICALS, INC.
To: ROYALTY SECURITY, LLC
Reel/Frame 051519/0511 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2010
From: AUSTAD, BRIAN C.; LESCARBEAU, ANDRE; YU, LIN-CHEN
To: INFINITY PHARMACEUTICALS, INC.
Reel/Frame 024954/0843 →
Continuity (3)
Continuation In Part 11965688 · Dec 27, 2007
Provisional Application 61017162 · Dec 27, 2007
Related Publication 20110009442A1 · Jan 13, 2011